Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
WARRINGTON, Pa. , April 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the closing of its previously announced underwritten
Article Date
April 24, 2023
This article is featured on another website.
Go to article
July 31, 2026
What Makes a Modern CRO? Inside HiRO’s Global Growth Story
Part 1 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 31, 2026
What Makes a Modern CRO? Inside HiRO’s Global Growth Story
Part 1 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…